We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Read MoreHide Full Article
Key Takeaways
Incyte rose 5.1% after partnering with QIAGEN to advance diagnostics for rare blood cancers.
QIAGEN will create a next-generation sequencing panel focused on mutCALR for MPNs patient selection.
Early data shows INCY's INCA033989 yields strong responses and targets mutCALR while sparing healthy cells.
Shares of Incyte (INCY - Free Report) gained 5.1% on Monday following the announcement of a global partnership with Netherlands-based QIAGEN N.V. (QGEN - Free Report) . The collaboration aims to develop a novel diagnostic panel to support INCY’s pipeline of investigational treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers representing about 40% of hematological malignancies.
The deal includes INCA033989, Incyte’s investigational monoclonal antibody targeting mutant calreticulin (mutCALR), currently in early-stage development for myelofibrosis (MF) and essential thrombocythemia (ET).
Per the agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology to accurately identify key gene alterations in MPNs with an initial focus on mutCALR, the second most common driver of MPNs.
Further, the panel will be validated on the Illumina NextSeq 550Dx platform for use with whole blood samples. QIAGEN will also assist with regulatory submissions and market access efforts in the United States, the EU and certain Asia-Pacific regions.
Year to date, shares of Incyte have gained 3.1% against the industry’s 0.9% decline.
Image Source: Zacks Investment Research
How the Deal Benefits INCY and QGEN
The strategic deal with QIAGEN benefits Incyte by advancing its precision medicine efforts in treating MPNs. Identifying genetic mutations like CALR is essential for guiding treatment decisions in these rare blood cancers. Through this partnership, Incyte will gain access to a globally available companion diagnostic that supports the use of its targeted therapy, INCA033989, for patients with mutCALR ET or MF.
By enabling widespread CALR testing, the collaboration improves patient selection for Incyte’s therapies, increasing the likelihood of better outcomes. It also strengthens Incyte’s position in the personalized medicine space and helps accelerate regulatory and market access for its mutCALR-targeted treatment across major regions.
Meanwhile, the partnership with Incyte enhances QIAGEN’s position in providing companion diagnostics services for the expanding range of biomarkers in onco-hematology, thus maximizing the utility of such services for both payors and patients.
INCY Reports Upbeat Data From 2 Phase I ET Studies
Incyte recently announced the first clinical data from the dose-escalation portion of two phase I studies evaluating the safety, tolerability and efficacy of INCA033989 in patients with high-risk ET who are resistant/intolerant to prior cytoreductive therapy. The candidate’s efficacy was measured by hematologic response and reduction in mutCALR variant allele frequency (VAF).
As of April 4, 2025, INCA033989 showed rapid and lasting platelet normalization in ET patients, especially at doses above 400 mg. At those doses, 86% of patients achieved a complete/partial hematologic response, with the majority (82%) achieving a complete response. Additionally, 89% of patients showed reduced mutCALR VAF, with 21% showing a >50% drop after just three treatment cycles.
An exploratory single-cell DNA sequencing study confirmed that INCA033989 selectively targets mutCALR cells, sparing healthy ones and restoring normal blood cell production. Bone marrow results also supported this, showing fewer diseased cells and more healthy ones, indicating potential for disease modification. The candidate was overall well-tolerated across all dosage strengths, with no dose-limiting toxicities observed. Per reports, only one patient discontinued treatment and one dose reduction due to treatment-emergent adverse events was observed.
Incyte is also gearing up to report additional data from the phase I study of INCA033989 in patients with MF. The company expects to advance the candidate into late-stage development for the MPNs indications in 2026, following discussions with regulatory authorities.
In the past 60 days, loss per share estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 17.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 61.3%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
Key Takeaways
Shares of Incyte (INCY - Free Report) gained 5.1% on Monday following the announcement of a global partnership with Netherlands-based QIAGEN N.V. (QGEN - Free Report) . The collaboration aims to develop a novel diagnostic panel to support INCY’s pipeline of investigational treatments for myeloproliferative neoplasms (MPNs), a group of rare blood cancers representing about 40% of hematological malignancies.
The deal includes INCA033989, Incyte’s investigational monoclonal antibody targeting mutant calreticulin (mutCALR), currently in early-stage development for myelofibrosis (MF) and essential thrombocythemia (ET).
Per the agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology to accurately identify key gene alterations in MPNs with an initial focus on mutCALR, the second most common driver of MPNs.
Further, the panel will be validated on the Illumina NextSeq 550Dx platform for use with whole blood samples. QIAGEN will also assist with regulatory submissions and market access efforts in the United States, the EU and certain Asia-Pacific regions.
Year to date, shares of Incyte have gained 3.1% against the industry’s 0.9% decline.
Image Source: Zacks Investment Research
How the Deal Benefits INCY and QGEN
The strategic deal with QIAGEN benefits Incyte by advancing its precision medicine efforts in treating MPNs. Identifying genetic mutations like CALR is essential for guiding treatment decisions in these rare blood cancers. Through this partnership, Incyte will gain access to a globally available companion diagnostic that supports the use of its targeted therapy, INCA033989, for patients with mutCALR ET or MF.
By enabling widespread CALR testing, the collaboration improves patient selection for Incyte’s therapies, increasing the likelihood of better outcomes. It also strengthens Incyte’s position in the personalized medicine space and helps accelerate regulatory and market access for its mutCALR-targeted treatment across major regions.
Meanwhile, the partnership with Incyte enhances QIAGEN’s position in providing companion diagnostics services for the expanding range of biomarkers in onco-hematology, thus maximizing the utility of such services for both payors and patients.
INCY Reports Upbeat Data From 2 Phase I ET Studies
Incyte recently announced the first clinical data from the dose-escalation portion of two phase I studies evaluating the safety, tolerability and efficacy of INCA033989 in patients with high-risk ET who are resistant/intolerant to prior cytoreductive therapy. The candidate’s efficacy was measured by hematologic response and reduction in mutCALR variant allele frequency (VAF).
As of April 4, 2025, INCA033989 showed rapid and lasting platelet normalization in ET patients, especially at doses above 400 mg. At those doses, 86% of patients achieved a complete/partial hematologic response, with the majority (82%) achieving a complete response. Additionally, 89% of patients showed reduced mutCALR VAF, with 21% showing a >50% drop after just three treatment cycles.
An exploratory single-cell DNA sequencing study confirmed that INCA033989 selectively targets mutCALR cells, sparing healthy ones and restoring normal blood cell production. Bone marrow results also supported this, showing fewer diseased cells and more healthy ones, indicating potential for disease modification. The candidate was overall well-tolerated across all dosage strengths, with no dose-limiting toxicities observed. Per reports, only one patient discontinued treatment and one dose reduction due to treatment-emergent adverse events was observed.
Incyte is also gearing up to report additional data from the phase I study of INCA033989 in patients with MF. The company expects to advance the candidate into late-stage development for the MPNs indications in 2026, following discussions with regulatory authorities.
Incyte Corporation Price and Consensus
Incyte Corporation price-consensus-chart | Incyte Corporation Quote
INCY’s Zacks Rank and Stocks to Consider
Incyte currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Immunocore (IMCR - Free Report) and Bayer (BAYRY - Free Report) . While IMCR currently sports a Zacks Rank #1 (Strong Buy), BAYRY carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, loss per share estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 17.6% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%.
BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 61.3%.
BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%.